- Home
- CUB vs TSHA Comparison
CUB vs TSHA Comparison
Compare CUB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- TSHA
- Stock Information
- Founded
- CUB 2024
- TSHA 2019
- Country
- CUB United States
- TSHA United States
- Employees
- CUB N/A
- TSHA N/A
- Industry
- CUB
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- TSHA Health Care
- Exchange
- CUB NYSE
- TSHA Nasdaq
- Market Cap
- CUB 315.9M
- TSHA 397.8M
- IPO Year
- CUB 2024
- TSHA 2020
- Fundamental
- Price
- CUB $10.35
- TSHA $2.10
- Analyst Decision
- CUB
- TSHA Strong Buy
- Analyst Count
- CUB 0
- TSHA 8
- Target Price
- CUB N/A
- TSHA $6.63
- AVG Volume (30 Days)
- CUB 31.7K
- TSHA 2.9M
- Earning Date
- CUB 01-01-0001
- TSHA 05-16-2025
- Dividend Yield
- CUB N/A
- TSHA N/A
- EPS Growth
- CUB N/A
- TSHA N/A
- EPS
- CUB N/A
- TSHA N/A
- Revenue
- CUB N/A
- TSHA $8,333,000.00
- Revenue This Year
- CUB N/A
- TSHA N/A
- Revenue Next Year
- CUB N/A
- TSHA N/A
- P/E Ratio
- CUB $45.21
- TSHA N/A
- Revenue Growth
- CUB N/A
- TSHA N/A
- 52 Week Low
- CUB $9.96
- TSHA $1.05
- 52 Week High
- CUB $10.55
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- TSHA 58.01
- Support Level
- CUB N/A
- TSHA $1.85
- Resistance Level
- CUB N/A
- TSHA $2.73
- Average True Range (ATR)
- CUB 0.00
- TSHA 0.27
- MACD
- CUB 0.00
- TSHA 0.04
- Stochastic Oscillator
- CUB 0.00
- TSHA 58.47
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.